Correlation Between Xbrane Biopharma and Hansa Biopharma

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Xbrane Biopharma and Hansa Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Xbrane Biopharma and Hansa Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Xbrane Biopharma AB and Hansa Biopharma AB, you can compare the effects of market volatilities on Xbrane Biopharma and Hansa Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Xbrane Biopharma with a short position of Hansa Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Xbrane Biopharma and Hansa Biopharma.

Diversification Opportunities for Xbrane Biopharma and Hansa Biopharma

0.14
  Correlation Coefficient

Average diversification

The 3 months correlation between Xbrane and Hansa is 0.14. Overlapping area represents the amount of risk that can be diversified away by holding Xbrane Biopharma AB and Hansa Biopharma AB in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Hansa Biopharma AB and Xbrane Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Xbrane Biopharma AB are associated (or correlated) with Hansa Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Hansa Biopharma AB has no effect on the direction of Xbrane Biopharma i.e., Xbrane Biopharma and Hansa Biopharma go up and down completely randomly.

Pair Corralation between Xbrane Biopharma and Hansa Biopharma

Assuming the 90 days trading horizon Xbrane Biopharma AB is expected to generate 1.45 times more return on investment than Hansa Biopharma. However, Xbrane Biopharma is 1.45 times more volatile than Hansa Biopharma AB. It trades about 0.02 of its potential returns per unit of risk. Hansa Biopharma AB is currently generating about -0.44 per unit of risk. If you would invest  16.00  in Xbrane Biopharma AB on October 25, 2024 and sell it today you would earn a total of  0.00  from holding Xbrane Biopharma AB or generate 0.0% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Xbrane Biopharma AB  vs.  Hansa Biopharma AB

 Performance 
       Timeline  
Xbrane Biopharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Xbrane Biopharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
Hansa Biopharma AB 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Hansa Biopharma AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in February 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Xbrane Biopharma and Hansa Biopharma Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Xbrane Biopharma and Hansa Biopharma

The main advantage of trading using opposite Xbrane Biopharma and Hansa Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Xbrane Biopharma position performs unexpectedly, Hansa Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Hansa Biopharma will offset losses from the drop in Hansa Biopharma's long position.
The idea behind Xbrane Biopharma AB and Hansa Biopharma AB pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.

Other Complementary Tools

Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges